Analgesics
Antiandrogens
Antihistamines
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
PPIs
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Meta analysis
 
Feedback
Home
c19early.org COVID-19 treatment researchLeritrelvirLeritrelvir (more..)
Melatonin Meta
Metformin Meta
Antihistamines Meta
Azvudine Meta Molnupiravir Meta
Bromhexine Meta
Budesonide Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta PPIs Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

    
  
Leritrelvir for COVID-19
2 studies from 58 scientists
1,399 patients in 1 country
Significantly lower risk for recovery and viral clearance.
2 studies from 2 independent teams (both from the same country) show significant benefit.
COVID-19 Leritrelvir studies. Dec 2024. c19early.org
0 0.5 1 1.5+ All studies 21% Recovery 21% Viral clearance 18% RCTs 21% Early 21% Favorsleritrelvir Favorscontrol
Home   Post   Share   @CovidAnalysis   Meta AnalysisMeta   Leritrelvir was adopted in 1 country. Submit updates/corrections. Summary.
Dec 3
Covid Analysis Leritrelvir for COVID-19: real-time meta analysis of 2 studies
Significantly lower risk is seen for recovery and viral clearance. 2 studies from 2 independent teams (both from the same country) show significant benefit. Meta analysis using the most serious outcome reported shows 21% [3‑35%..
Jul 6
Zhao et al., Quantitative Biology, doi:10.1002/qub2.60 Assessing the inhibition efficacy of clinical drugs against the main proteases of SARS‐CoV‐2 variants and other coronaviruses
In Vitro study showing that leritrelvir and GC376 remained effective against some nirmatrelvir- and ensitrelvir-resistant Mpro mutants. Leritrelvir showed better broad-spectrum activity against other pathogenic coronaviruses compared to e..
Mar 29
Chen et al., Nature Microbiology, doi:10.1038/s41564-024-01618-9 Preclinical evaluation of the SARS-CoV-2 Mpro inhibitor RAY1216 shows improved pharmacokinetics compared with nirmatrelvir
In Vitro and K18-hACE2 transgenic mouse study showing the preclinical efficacy of RAY1216, an inhibitor of the SARS-CoV-2 main protease (Mpro), against multiple SARS-CoV-2 variants. RAY1216 forms a covalent bond with the catalytic cystein..
Jan 31
Zhan et al., eClinicalMedicine, doi:10.1016/j.eclinm.2023.102359 Leritrelvir for the treatment of mild or moderate COVID-19 without co-administered ritonavir: a multicentre randomised, double-blind, placebo-controlled phase 3 trial
17% improved recovery (p=0.002) and 16% improved viral clearance (p=0.01). RCT 1,359 COVID-19 outpatients showing faster recovery with leritrelvir monotherapy (without ritonavir), 251 vs. 271 hours, and improved viral clearance. There were no significant differences in adverse events between groups.
Sep 30
2023
Wang et al., eClinicalMedicine, doi:10.1016/j.eclinm.2023.102189 Antiviral efficacy of RAY1216 monotherapy and combination therapy with ritonavir in patients with COVID-19: a phase 2, single centre, randomised, double-blind, placebo-controlled trial
35% faster recovery (p=0.04) and 21% improved viral clearance (p=0.01). RCT 60 hospitalized COVID-19 patients in China showing imporoved recovery and viral clearance with RAY1216, a 3CLpro inhibitor.
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Thanks for your feedback! Please search before submitting papers and note that studies are listed under the date they were first available, which may be the date of an earlier preprint.
Submit